Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)

Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J. Greene; Susan G. Sherman; Katherine H.A. Footer; Richard T. D’Aquila; Alex Carballo-Diéguez; Thomas J. Hope

doi:10.1007/s10461-019-02703-5

Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)

Christine Tagliaferri Rael^*, Michelle Martinez, Rebecca Giguere, Walter Bockting, Caitlin MacCrate, Will Mellman, Pablo Valente, George J. Greene, Susan G. Sherman, Katherine H.A. Footer, Richard T. D’Aquila, Alex Carballo-Diéguez, Thomas J. Hope

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

There are several long-acting biomedical HIV prevention products in the development pipeline, including injections and implanted medication delivery devices (IMDDs). It is critical to understand concerns and preferences on the use of these products in populations that shoulder a disproportionate burden of the HIV epidemic, such as transgender women. This will allow researchers and public health professionals to construct interventions tailored to the needs of these women to promote optimal use of these tools. In studies of other biomedical HIV prevention products (e.g., oral PrEP) it is clear that transgender women have unique concerns related to the use of these strategies. This may have an impact on this group’s uptake and sustained use of longacting HIV prevention products. This study conducted four focus groups with N = 18 transgender women in New York City to understand their concerns and preferences on long-acting PrEP injections and IMDDs. Findings showed that participants were overwhelmingly positive about long-acting HIV prevention strategies, though they had some apprehensions. Overall, participants felt that injections and IMDDs could help address adherence challenges, and that transgender-specific needs should be addressed during clinical trials. Also, there were concerns related to injection or IMDD logistics, concerns about injections’ or IMDDs’ presence in the body, and familiarity with these products affected participants’ opinions on them. Findings from this work can be used to inform protocols, measures, materials, and adherence interventions in future initiatives for transgender women using PrEP injections or IMDDs.

Original language	English (US)
Pages (from-to)	1452-1462
Number of pages	11
Journal	AIDS and behavior
Volume	24
Issue number	5
DOIs	https://doi.org/10.1007/s10461-019-02703-5
State	Published - May 1 2020

Funding

Data collection support was provided by Project AFFIRM (R01 HD079603; Principal Investigator, Walter Bockting, Ph.D.) and a generous grant from the Mac AIDS Fund (MAF CU13-3233; Principal Investigator: Walter Bockting, Ph.D.). The first author is supported by a K01 Award from the National Institute of Mental Health (K01 MH115785; Principal Investigator: Christine Tagliaferri Rael, Ph.D.) from the National Institute of Mental Health at the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute and Columbia University (P30 MH43520; Center Principal Investigator: Robert Remien, Ph.D.). Additionally, research was supported by SLAP-HIV (UM1 AI120184; Principal Investigator, Tomas Hope, Ph.D.) and the Third Coast Center for AIDS Research (P30 AI117943; Principal Investigator, Richard D’Aquila, M.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The research team would like to thank all participants for their time, hard work, and critical insight. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Data collection support was provided by Project AFFIRM (R01 HD079603; Principal Investigator, Walter Bockting, Ph.D.) and a generous grant from the Mac AIDS Fund (MAF CU13-3233; Principal Investigator: Walter Bockting, Ph.D.). The first author is supported by a K01 Award from the National Institute of Mental Health (K01 MH115785; Principal Investigator: Christine Tagliaferri Rael, Ph.D.) from the National Institute of Mental Health at the?HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute and Columbia University (P30 MH43520; Center Principal Investigator: Robert Remien, Ph.D.). Additionally, research was supported by SLAP-HIV (UM1 AI120184; Principal Investigator, Tomas Hope, Ph.D.) and the Third Coast Center for AIDS Research (P30 AI117943; Principal Investigator, Richard D?Aquila, M.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The research team would like to thank all participants for their time, hard work, and critical insight.

Keywords

Biomedical HIV prevention
Cabotegravir
Longacting PrEP
PrEP implants
PrEP injections
Pre-exposure prophylaxis
Systemic PrEP
Transgender women
Transwomen

ASJC Scopus subject areas

Social Psychology
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10461-019-02703-5

Cite this

Rael, C. T., Martinez, M., Giguere, R., Bockting, W., MacCrate, C., Mellman, W., Valente, P., Greene, G. J., Sherman, S. G., Footer, K. H. A., D’Aquila, R. T., Carballo-Diéguez, A., & Hope, T. J. (2020). Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs). AIDS and behavior, 24(5), 1452-1462. https://doi.org/10.1007/s10461-019-02703-5

@article{872d33477a1d4251bc8fabda995b50ee,

title = "Transgender Women{\textquoteright}s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)",

abstract = "There are several long-acting biomedical HIV prevention products in the development pipeline, including injections and implanted medication delivery devices (IMDDs). It is critical to understand concerns and preferences on the use of these products in populations that shoulder a disproportionate burden of the HIV epidemic, such as transgender women. This will allow researchers and public health professionals to construct interventions tailored to the needs of these women to promote optimal use of these tools. In studies of other biomedical HIV prevention products (e.g., oral PrEP) it is clear that transgender women have unique concerns related to the use of these strategies. This may have an impact on this group{\textquoteright}s uptake and sustained use of longacting HIV prevention products. This study conducted four focus groups with N = 18 transgender women in New York City to understand their concerns and preferences on long-acting PrEP injections and IMDDs. Findings showed that participants were overwhelmingly positive about long-acting HIV prevention strategies, though they had some apprehensions. Overall, participants felt that injections and IMDDs could help address adherence challenges, and that transgender-specific needs should be addressed during clinical trials. Also, there were concerns related to injection or IMDD logistics, concerns about injections{\textquoteright} or IMDDs{\textquoteright} presence in the body, and familiarity with these products affected participants{\textquoteright} opinions on them. Findings from this work can be used to inform protocols, measures, materials, and adherence interventions in future initiatives for transgender women using PrEP injections or IMDDs.",

keywords = "Biomedical HIV prevention, Cabotegravir, Longacting PrEP, PrEP implants, PrEP injections, Pre-exposure prophylaxis, Systemic PrEP, Transgender women, Transwomen",

author = "Rael, {Christine Tagliaferri} and Michelle Martinez and Rebecca Giguere and Walter Bockting and Caitlin MacCrate and Will Mellman and Pablo Valente and Greene, {George J.} and Sherman, {Susan G.} and Footer, {Katherine H.A.} and D{\textquoteright}Aquila, {Richard T.} and Alex Carballo-Di{\'e}guez and Hope, {Thomas J.}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = may,

day = "1",

doi = "10.1007/s10461-019-02703-5",

language = "English (US)",

volume = "24",

pages = "1452--1462",

journal = "AIDS and behavior",

issn = "1090-7165",

publisher = "Springer New York",

number = "5",

}

Rael, CT, Martinez, M, Giguere, R, Bockting, W, MacCrate, C, Mellman, W, Valente, P, Greene, GJ, Sherman, SG, Footer, KHA, D’Aquila, RT, Carballo-Diéguez, A & Hope, TJ 2020, 'Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)', AIDS and behavior, vol. 24, no. 5, pp. 1452-1462. https://doi.org/10.1007/s10461-019-02703-5

Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs). / Rael, Christine Tagliaferri; Martinez, Michelle; Giguere, Rebecca et al.
In: AIDS and behavior, Vol. 24, No. 5, 01.05.2020, p. 1452-1462.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies

T2 - The Case of Injections and Implanted Medication Delivery Devices (IMDDs)

AU - Rael, Christine Tagliaferri

AU - Martinez, Michelle

AU - Giguere, Rebecca

AU - Bockting, Walter

AU - MacCrate, Caitlin

AU - Mellman, Will

AU - Valente, Pablo

AU - Greene, George J.

AU - Sherman, Susan G.

AU - Footer, Katherine H.A.

AU - D’Aquila, Richard T.

AU - Carballo-Diéguez, Alex

AU - Hope, Thomas J.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - There are several long-acting biomedical HIV prevention products in the development pipeline, including injections and implanted medication delivery devices (IMDDs). It is critical to understand concerns and preferences on the use of these products in populations that shoulder a disproportionate burden of the HIV epidemic, such as transgender women. This will allow researchers and public health professionals to construct interventions tailored to the needs of these women to promote optimal use of these tools. In studies of other biomedical HIV prevention products (e.g., oral PrEP) it is clear that transgender women have unique concerns related to the use of these strategies. This may have an impact on this group’s uptake and sustained use of longacting HIV prevention products. This study conducted four focus groups with N = 18 transgender women in New York City to understand their concerns and preferences on long-acting PrEP injections and IMDDs. Findings showed that participants were overwhelmingly positive about long-acting HIV prevention strategies, though they had some apprehensions. Overall, participants felt that injections and IMDDs could help address adherence challenges, and that transgender-specific needs should be addressed during clinical trials. Also, there were concerns related to injection or IMDD logistics, concerns about injections’ or IMDDs’ presence in the body, and familiarity with these products affected participants’ opinions on them. Findings from this work can be used to inform protocols, measures, materials, and adherence interventions in future initiatives for transgender women using PrEP injections or IMDDs.

AB - There are several long-acting biomedical HIV prevention products in the development pipeline, including injections and implanted medication delivery devices (IMDDs). It is critical to understand concerns and preferences on the use of these products in populations that shoulder a disproportionate burden of the HIV epidemic, such as transgender women. This will allow researchers and public health professionals to construct interventions tailored to the needs of these women to promote optimal use of these tools. In studies of other biomedical HIV prevention products (e.g., oral PrEP) it is clear that transgender women have unique concerns related to the use of these strategies. This may have an impact on this group’s uptake and sustained use of longacting HIV prevention products. This study conducted four focus groups with N = 18 transgender women in New York City to understand their concerns and preferences on long-acting PrEP injections and IMDDs. Findings showed that participants were overwhelmingly positive about long-acting HIV prevention strategies, though they had some apprehensions. Overall, participants felt that injections and IMDDs could help address adherence challenges, and that transgender-specific needs should be addressed during clinical trials. Also, there were concerns related to injection or IMDD logistics, concerns about injections’ or IMDDs’ presence in the body, and familiarity with these products affected participants’ opinions on them. Findings from this work can be used to inform protocols, measures, materials, and adherence interventions in future initiatives for transgender women using PrEP injections or IMDDs.

KW - Biomedical HIV prevention

KW - Cabotegravir

KW - Longacting PrEP

KW - PrEP implants

KW - PrEP injections

KW - Pre-exposure prophylaxis

KW - Systemic PrEP

KW - Transgender women

KW - Transwomen

UR - http://www.scopus.com/inward/record.url?scp=85074607707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074607707&partnerID=8YFLogxK

U2 - 10.1007/s10461-019-02703-5

DO - 10.1007/s10461-019-02703-5

M3 - Article

C2 - 31654172

AN - SCOPUS:85074607707

SN - 1090-7165

VL - 24

SP - 1452

EP - 1462

JO - AIDS and behavior

JF - AIDS and behavior

IS - 5

ER -

Transgender Women’s Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this